Chiesi Group has three production plants:
The plants produce in the whole more than 73 million units per year.
The production plant in Parma covers a total area of more than fifteen thousand square metres, and it is the strategic hub for the production and distribution of our products, an international supply centre that exports to more than 60 countries.
The Parma plant produces solid form medicinal products, such as tablets and dry powder inhalers; solutions and suspensions for inhalation, either pressurised or sterile single-dose vials; vials of sterile suspension for endotracheal administration; liquid forms such as drops, syrups and nasal sprays.
The plant has been successfully inspected several times by regulatory authorities from a number of countries: the U.S. Food and Drug Administration, the Canadian Therapeutic Products Program, the Chinese CFDA, Russian GMP & Quality Management Inspectorate, the Brazilian Health Agency ANVISA and the Italian AIFA (Italian Agency for Pharmaceuticals). A Health and Work Safety Management System complying with OHSAS 18001:2007 standard and an Environment Management system in accordance with ISO 14001:2004 is in place and has been certified.
Almost 490 people work at the production plant of Parma.
The production plant in Blois specialises in capsules and tablet blister packaging, in the final assembly and production steps of the metered-dose spray inhalers, for which the plant has an ample refrigerated storage facility. The site is equipped for direct distribution to the customers for the French market and for export purposes.
There is also a new production, packaging, storage and control department focusing on the new dry powder inhaler, which supports the activities of the Parma plant.
Over 70 people work at the Bois plant.
The Brazilian production lines prepare solid forms, liquids and solutions, pressurised suspensions for inhalation with eco-friendly propellant. The target markets, in addition to the local one, are the other Group’s affiliates, including Italy, because of AIFA approval (The Italian Medicines Agency) following regular inspections on site, the United Kingdom, and for export to licensees and distributors.
Over 120 people work at the Santana de Parnaíba site.
